GLP-1 and Parkinson’s Disease: A Comprehensive Review of Biology, Mechanisms and Efficacy
Cells · 2026
DOI: 10.3390/cells15090804 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2026. Verfasst von Roxana Mezabrovschi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK. Hauptthemen laut MEDLINE: Parkinson Disease, Glucagon-Like Peptide 1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 188 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Free Charity PhD studentship Fund.
Abstract (Originalsprache)
Neurodegenerative disorders, including Parkinson’s disease (PD), are largely treated with symptomatic therapies, underscoring the need for strategies that target underlying disease mechanisms. Glucagon-like peptide-1 (GLP-1) and its receptor (GLP-1R), a class B G protein-coupled receptor best known for metabolic regulation, have attracted interest due to the increasing evidence of central nervous system (CNS) actions. This review synthesises mechanistic, preclinical, and clinical evidence examining GLP-1R signalling in PD and related neurodegenerative contexts. We integrate findings from cellular and animal models with early-phase clinical studies of GLP-1 receptor agonists (GLP-1RAs). Across experimental systems, GLP-1R activation engages conserved intracellular pathways—cAMP/PKA, PI3K/Akt, and ERK—that regulate mitochondrial function, oxidative stress, autophagy-lysosomal dynamics, and inflammatory signalling. In PD-relevant models, these pathways intersect with key pathogenic features, including α-synuclein accumulation, dopaminergic neuron vulnerability, and glial reactivity. Clinical studies to date demonstrate acceptable safety and tolerability, alongside biomarker evidence of central pathway engagement and variable effects on motor and non-motor outcomes. However, uncertainties remain regarding CNS target engagement, peripheral versus CNS mechanisms, and disease-stage dependence. Overall, the current evidence positions GLP-1R signalling as a biologically plausible therapeutic pathway in PD that warrants further mechanistic clarification and rigorous evaluation in ongoing and future clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.
ORCID-Profile: Roxana Mezabrovschi, Matthew E Gegg
Förderung
- Free Charity PhD studentship Fund
Zitieren
APA
Mezabrovschi, R., Gegg, M. E., & Schapira, A. H. V. (2026). GLP-1 and Parkinson’s Disease: A Comprehensive Review of Biology, Mechanisms and Efficacy. Cells. https://doi.org/10.3390/cells15090804
Vancouver
Mezabrovschi R, Gegg ME, Schapira AHV. GLP-1 and Parkinson’s Disease: A Comprehensive Review of Biology, Mechanisms and Efficacy. Cells. 2026. doi:10.3390/cells15090804
BibTeX
@article{Mezabrovschi2026,
author = {Mezabrovschi, Roxana and Gegg, Matthew E and Schapira, Anthony H V},
title = {GLP-1 and Parkinson’s Disease: A Comprehensive Review of Biology, Mechanisms and Efficacy},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15090804}
}
EUVIMED